Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Novo Nordisk A/S Class B (NOVG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
115.30 +0.26    +0.23%
05:20:33 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DK0062498333 
S/N:  A3EU6F
  • Volume: 2,308
  • Bid/Ask: 115.60 / 115.74
  • Day's Range: 113.84 - 116.18
Novo Nordisk B 115.30 +0.26 +0.23%

NOVG Income Statement

 
Featured here, the Income Statement (earnings report) for Novo Nordisk A/S Class B, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Revenue 65863 58731 54300 53367
Revenue 65863 58731 54300 53367
Other Revenue, Total - - - -
Cost of Revenue, Total 10014 9713 7856 8182
Gross Profit 55849 49018 46444 45185
Total Operating Expenses 37683 31818 30412 28360
Selling/General/Admin. Expenses, Total 18626 14075 15414 13483
Research & Development 9046 8128 7127 6728
Depreciation / Amortization -6421 2525 2177 1719
Interest Expense (Income) - Net Operating -542 - - -
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 6960 -2623 -2162 -1752
Operating Income 28180 26913 23888 25007
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets 37 - - -
Other, Net 523 -1150 -366 270
Net Income Before Taxes 27620 28063 24254 24737
Provision for Income Taxes 5657 5585 4826 4923
Net Income After Taxes 21963 22478 19428 19814
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 21963 22478 19428 19814
Total Extraordinary Items - - - -
Net Income 21963 22478 19428 19814
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 21963 22478 19428 19814
Dilution Adjustment -13.24 33 -0.719 1.05
Diluted Net Income 21976.24 22445 19428.72 19812.95
Diluted Weighted Average Shares 4477.4 4489 4502.6 4513.2
Diluted EPS Excluding Extraordinary Items 4.91 5 4.32 4.39
DPS - Common Stock Primary Issue 6.4 - 3 -
Diluted Normalized EPS 4.05 3.91 3.37 3.43
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVOb Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
HH HH
HH HH Jun 12, 2023 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My investment propensity test was surprising that Jim Simon, a Renaissance technology, had the most stocks he owned, but it was even more surprising that Novo Nordisk AS. Because it was the only event I recommended to my friend. HHH
Terrible Investor
TerribleInvestor Apr 13, 2023 7:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Boooooom! 30%.
Terrible Investor
TerribleInvestor Jan 03, 2023 11:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very very bullish!
Terrible Investor
TerribleInvestor Jan 03, 2023 11:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Those dislikes didnt age well
Karsten Vester
Karsten Vester Jan 03, 2023 11:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dislikes dont know anything obviously
Toby Brunt
Toby Brunt Apr 19, 2022 5:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
HH HH
HH HH Apr 19, 2022 5:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I used to do the same thing. In the case of novice investment, we try to find out the reason for the fall and rise in stock prices. It's a futile act. The rise and fall in stock prices are just for Manipulators to move in a predetermined scenario. So a successful investment is a quick insight into Manipulators' scenarios. HHH
Sandy SS
Sandy SS Feb 09, 2022 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New Target 825 by EOM
Sandy SS
Sandy SS Feb 09, 2022 8:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New Target 825
Terrible Investor
TerribleInvestor Nov 25, 2021 5:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Consolidating nicely for leg up to 850!🌟
Ralf Adams
Ralf Adams Feb 11, 2021 4:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
Candy Man
Candy Man Jan 14, 2021 4:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bullish??
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No. Funds are selling. Time to wait to go long...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email